Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Yale School of Medicine, New Haven, Connecticut, United States

Moffitt Cancer Center, Tampa, Florida, United States

Massachusetts General Hospital, Boston, Massachusetts, United States

Henry Ford Hospital, Detroit, Michigan, United States

Sarah Cannon Research Institute, Nashville, Tennessee, United States

Texas Oncology Baylor University Medical Center, Dallas, Texas, United States

Virginia Cancer Specialists, Fairfax, Virginia, United States

Hospital 12 de Octubre, Usera, Madrid, Spain

Hospital Universitari Vall d'Hebron (VHIO), Barcelona, Spain

Hospital Universitario Ramón y Cajal, Madrid, Spain

NEXT Oncology Hospital Quironsalud, Madrid, Spain

Sarah Cannon Research Institute UK, London, London, United Kingdom

The Christie NHS Foundation Trust, Manchester, Wilmslow Rd, United Kingdom

The Clatterbridge Cancer Centre, Liverpool, United Kingdom